Author

J Nordanstig

Institution: University of Gothenburg

Observed institution: University of Gothenburg

OpenAlex ID: A5159666321

Effects of semaglutide on walking distance, symptoms and rescue treatment by baseline medical therapy and LDL cholesterol levels: insights from the STRIDE trial

2026 · M Bonaca, A M Catarig, et al. · European Heart Journal

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

2026 · E S Stroes, R S Rosenson, et al. · European Heart Journal

Design and baseline data of AZURE-LDL, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD

2026 · E S Stroes, M Koren, et al. · European Heart Journal

Works count: 3

Citation count:

H-index:

I10-index: